Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors N Rudra-Ganguly, C Lowe, C Virata, M Leavitt, L Jin, B Mendelsohn, J Snyder, H Aviña, C Zhang, DL Russell, M Mattie, PYang, B Randhawa, G Liu, F Malik, M Vest, JD Abad, CC Kemball, R Hubert, S Karki, B Anand, Z An, J Grant, JE Dick, F Doñate et. al.
Title AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts
Journal Blood
Abstract Text Blood 2015 126(23):3806


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
AGS62P1 AGS62P1 1 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
AGS62P1 FLT3 Antibody 4 AGS62P1 is a human anti-FLT3 antibody in conjugation with a microtubule disrupting agent, which may have anti-tumor activity (Blood 2015 126(23):3806, PMID: 29757653).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 positive acute myeloid leukemia predicted - sensitive AGS62P1 Preclinical - Patient cell culture Actionable In a preclinical study, AGS62P1 inhibited growth of FLT3-positive acute myeloid leukemia cell lines in culture, and led to tumor growth inhibition and regression in patient-derived xenograft (PDX) models (Blood 2015 126(23):3806). detail...